Micafungin: A New Echinocandin
Authors:
Open Access
- 15 April 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (8) , 1171-1178
Abstract
Micafungin, a potent inhibitor of 1,3-β-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for useKeywords
This publication has 55 references indexed in Scilit:
- Micafungin: pharmacology, experimental therapeutics and clinical applicationsExpert Opinion on Investigational Drugs, 2005
- Multiechinocandin- and Multiazole-ResistantCandida parapsilosisIsolates Serially Obtained during Therapy for Prosthetic Valve EndocarditisAntimicrobial Agents and Chemotherapy, 2005
- Micafungin Enhances Neutrophil Fungicidal Functions against Candida PseudohyphaeAntimicrobial Agents and Chemotherapy, 2004
- Echinocandin antifungal drugsThe Lancet, 2003
- Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrobial Agents and Chemotherapy, 2003
- Antifungal Susceptibility ofCandidaBiofilms: Unique Efficacy of Amphotericin B Lipid Formulations and EchinocandinsAntimicrobial Agents and Chemotherapy, 2002
- Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy MenAntimicrobial Agents and Chemotherapy, 2002
- Micafungin sodium (FK-463)Drugs of Today, 2002
- Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 against Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2001
- Lipopeptide inhibitors of fungal glucan synthaseMedical Mycology, 1997